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osting by EAbstract A simple, rapid, sensitive and accurate spectrophotometric method for the determination
of captopril in pure form and pharmaceutical formulations is developed. The procedure is based on
the reaction of copper(II) with captopril in the presence of neocuproine (NC) (2,9-dimethyl-1,10-
phenanthroline) reagent in acetate buffer at pH 5.0. Copper(II) is reduced easily by captopril to
Cu(I)–neocuproine complex, which shows an absorption maximum at 448 nm. Beer’s law was
obeyed in the concentration range 0.3–3.0 lg mL1 with a minimum detection limit (LOD) of
0.039 lg mL1 and a quantiﬁcation limit (LOQ) of 0.129 lg mL1. For more accurate results, Ring-
bom optimum concentration ranges was 0.5–2.7 lg mL1. The apparent molar absorbtivity and
Sandell sensitivity were calculated. The validity of the proposed method was tested by analyzing
the pure and pharmaceutical formulations and compared well with those obtained by the ofﬁcial
method and demonstrated good accuracy and precision.
ª 2010 King Saud University. All rights reserved.1. Introduction
Captopril, (Fig. 1), 1-(3-mercapto-2-D-methyl-1-oxoproppyl)-l-
proline (S,S), is used therapeutically as an antihypertensiveom (A.A. Gouda).
ity. All rights reserved. Peer-
d University.
lsevieragent. It acts as a potent and speciﬁc inhibitor of angioten-
sin-converting enzyme. In addition, it is used in the manage-
ment of heart failure, following myocardial infraction and in
diabetic nephropathy. About 60–75% of a dose of CPL is ab-
sorbed from the gastro-intestinal tract and peak plasma con-
centration is achieved in about an hour. About 30% of the
drug is bound to plasma protein (Parﬁtt et al., 1999). The drug
is listed in United States Pharmacopoeia (United States Phar-
macopoeia et al., 2004), which recommends an HPLC method
for its assay in bulk and tablet formulations.
Several methods have been reported for the quantitative
determination of CPL in dosage forms and biological ﬂuids,
including: GC–MS (Liu et al., 1995, 1998; Rose, 1998), HPLC
(Huang et al., 2006; Nishikawa et al., 2004; El-Gindy et al.,
Figure 1 The chemical structure of captopril and neocuproine.
160 A.A. Gouda, A.S. Amin2004; Russell et al., 1997; Bahmaei et al., 1997; Bald and
Sypniewski, 1997; Kok et al., 1997; Favaro and Fiorani,
1996; Salazar et al., 1999; Battermann et al., 1998; Khedr
and El-Sherief, 1998), electrochemistry (Stefan et al., 2000a;
Stefan et al., 2000b; Fraga et al., 1998; Riberio et al., 2003),
chemiluminescence (Ouyang et al., 1999), capillary electropho-
resis (Hillaert and Van-den-Bossche, 1999), ﬂow injection
chemiluminescence (Li et al., 2001), titrimetry (El-Brashy,
1995), atomic absorption spectrophotometry (El-Reis et al.,
2000) and several spectrophotometric methods have been re-
ported in the literature (Askal, 1991; Sastry et al., 1991a;
Mahadik et al., 1991; Sastry et al., 1991b; Albero et al.,
1993; Ibraham, 1994; Jovanovic et al., 1995; Sastry et al.,
1996; Huan et al., 2005; Sachan et al., 1997; Sastry et al.,
1998; Gumieniczek et al., 1998; Karli´cek and Solich, 1998; El
Walily et al., 1999; Shingare and Kale, 2000; Basavaiah et al.,
2003a, b, c; Tzanavaras et al., 2003; Srivastava et al., 2003;
Basavaiah and Nagegowda, 2004a; Basavaiah and Nage-
gowda, 2004b; Hosseinimehr et al., 2004; El-Shabrawy et al.,
2004; Rahman et al., 2005; Huan et al., 2005; Shama et al.,
2006; Chandru and Sharada, 2007; Suarez et al., 2007; Belal
et al., 2008; Haggag et al., 2008; El-Enany et al., 2008). Com-Table 1 Comparison between spectrophotometric methods for the
Method kmax (nm) Be
(l
FeCl3 + bipyridyl
Residual iodine
Residual iodine–starch complex
523
351
620
0.2
Palladium(II) chloride 380 up
Ecess sodium nitrite/0.25 M HCl/cresyl fast violet acetate 555 0.1
Excess KBrO3 + celestine blue 540 0.4
Carbon disulphide + divalent metals: cobalt(II)
Pallidium(II)
Nikel(II)
390
450
364
16
40
30
Sodium metavanadate in acetic acid medium+ ferroin 510 2.5
Excess of iodate in sulphuric acid medium. 460 ra
Excess of chloramine-T + metol and sulphanilic acid 520 0–
Excess bromate–bromide reagent + methyl orange 510 0.2
DTNB reagent 412 1–
Potassium iodate in HCl medium+ CCl4 510 12
Potassium permanganate in acidic medium
+methylene blue (MB)
Acid blue 74 (AB)
Acid red 73 (AR)
Amaranth dye (AM)
Acid orange 7 (AO)
660
610
510
520
485
0.4
0.3
0.5
0.4
0.5
Hexacyanoferrate(III) 510 0.2
2,4-Dinitroﬂuorobenzene (DNFB) 2.4
4-chloro-7-nitro-2,1,3-benzoxadiazole (NBD-Cl) 420 –
2,6-dichloroquinone-4-chlorimide (DCQ)
in dimethylsulphoxide.
443 10
Cu(II) + neocopoin 448 0.3parison between the previous spectrophotometric methods for
the determination of captopril are shown in Table 1. These
methods suffer from a variety of disadvantages, such as use
of sophisticated and time consuming techniques, require
expensive instruments, low sensitivity, heating, extraction, re-
quire nonaqueous media and have higher Beer’s law ranges.
The formation of the charge transfer complex between
Cu(I) and neocuproine (NC) (2,9-dimethyl-1,10-phenanthro-
line) is the basis of the existing spectrophotometric method
for the determination of trace amounts of reducing agents
(Greenwood and Earnshaw, 1997). This was previously used
to determine the biochemically important reductants such as
cysteine (T¨utem and Apak, 1991), Vitamin E (T¨utem et al.,
1997), ascorbic acid (Guclu¨ et al., 2005), isoniazide (Safavi
et al., 2004), certain proton pump inhibitors (Syed and Syeda,
2007) and ceftazidime (Moreno and Salgado, 2008) can be
determined by reduction of Cu(II), followed by treating the
Cu(I) with chromogenic reagent neocuproine.
The aim of the present study is to apply simple, accurate,
selective, reproducible, and high sensitivity spectrophotometric
method of the determination of captopril in pure form and
pharmaceutical formulations based on its reducing ability.2. Experimental
2.1. Apparatus
All absorption spectra were made using Kontron 930 (UV–
Visible) spectrophotometer (German) with a scanning speed
of 200 nm/min and a band width of 2.0 nm, equipped withdetermination of captopril.
er’s law
g mL1)
Detection
limits (lg mL1)
Molar absorpitivity
(l mol1 cm1)
Reference
5–25 – – 26
to 5 · 104 M 2.17 1.875 · 103 32
–0.5 33
–4.0 36
–48
–120
–80
0.878
3.479
1.838
3.00 · 103
1.85 · 103
1.30 · 103
39
–20 0.18 7.31 · 103 44
nge 50–400 – 0.38 · 103 46
30 0.95 5.23 · 103 47
5–2.0 – 7.08 · 104 48
10 · 105 M 3.2 · 107 M 13,553 49
0–520 – – 51
–12.5
–10
–11
–8.3
–9.3
0.106
0.063
0.145
0.093
0.134
1.74 · 104
2.98 · 104
1.87 · 104
2.63 · 104
2.35 · 104
53
5–12.00 0.08 9.14 · 103 55
–16.8 – – 56
– – 57
–50 0.66 – 58
–3.0 0.056 4.223 · 104 Present work
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Copper(II)–neocuproine reagent for spectrophotometric determination 16110 mm matched quartz cells. Hanna pH-meter instrument
(Portogal) (HI: 9321) was used for checking the pH measure-
ments. All experiments were performed at 25 C.
2.2. Materials
An authentic sample of captopril was kindly supplied by Bris-
tol Myers Squibb Egypt Co., Giza, Egypt. The commercial
preparations were bought from the local market.
2.3. Standard solutions
A stock solution 1000 lg mL1 of captopril was prepared by
dissolving 0.1 g of captopril in 100 mL of bidistilled water.
The standard solution was stable for one week when kept in
the refrigerator. Working standards were prepared by appro-
priately diluting the above solution with the same solvent.
2.4. Reagents
All reagents were of analytical reagent grade. Double distilled
water was used throughout the study.
A stock solution 1.0 · 102 M of Cu(II) was prepared by
dissolving 0.241 g of Cu(NO3)2Æ3H2O (Merck) in water and
diluting to the mark in a 100 ml standard ﬂask.
A 5.0 · 103 M stock solution of neocuproine hemihydrate
(Merck) was prepared by dissolving 0.054 g of reagent in etha-
nol in a 50 mL standard ﬂask and diluting to the mark with
the same solvent.
Acetate buffer solutions of acetic acid–sodium acetate (pH
3.0–7.0) were prepared by following the standard methods.
The pH of stock solution was adjusted to an appropriate value
by addition of 0.2 M hydrochloric acid or sodium hydroxide
with the help of pH meter (Perrin and Dempsey, 1974).
2.5. Recommended analytical procedure
Two mL of 5.0 · 103 M neocuproin solution, 1.0 mL of
1.0 · 102 M Cu(II) solution, 3.0 mL acetate buffer solution
(pH 5.0) and a suitable volume (0.06–0.6 mL) of captopril stan-
dard solution 50 lg mL1 were placed in a 10 mL volumetric
ﬂask and mixed. After 150 s, the absorption was measured at
448 nmagainst a neocuproin–copper(II) solution reagent blank.
2.5.1. Analysis of pharmaceutical formulations
Twenty tablets of the drug were weighed, grounded to a ﬁne
powder and mixed. A sample equivalent to approximately
10 mg of captopril was weighed accurately, transferred into a
100 mL calibrated ﬂask and diluted to volume with water.
Then, mixed well for 10 min using a magnetic stirrer to aid dis-
solution and ﬁltered through a sintered glass crucible G4. An
appropriate volume of the ﬁltrate was diluted further with
water so that the concentration of captopril in the ﬁnal solu-
tion was within the working range. The recommended proce-
dures under calibration curve were then performed.Time, s
Figure 2 Kinetic curves for reduction of Cu(II)–neocuproine at
different concentrations of captopril: (a) 0.5 lg mL1; (b)
1.0 lg mL1; (c) 1.5 lg mL1; (d) 2.0 lg mL1; (e) 2.5 lg mL1;
(f) 3.0 lg mL1.3. Results and discussion
Captopril as all thiols was expected to undergo to some extent
oxidative degradation such as the formation of disulphide andthis suggests the investigation of an analytical procedure based
on the speciﬁc reactivity of the thiol group.
The development of direct spectrophotometric methods for
thiols is still a difﬁcult task. The problem is to ﬁnd a reaction
that gives a minimum of side-products and interferences and a
simple procedure.
Although reaction with Cu(II) ions is among the most com-
monly used procedures for determination of thiols, the only
spectrophotometric method (Gawargious et al., 1976) utilizing
this reaction is indirect and based on addition of excess Cu(II),
collection of the Cu(I) mercaptide formed and spectophoto-
metric measurement of the unreacted Cu(II) ions left in the
solution:4RSHþ 2Cu2þ ! R-S-S-Rþ 2RSCuþ 4Hþ
The present work offers a quite different approach. When
the copper(II)–neocuproine complex is used as the reagent,
precipitation of Cu(I) mercaptide does not take place. Instead,
the orange-yellow Cu(I)–neocupoine chelate is formed once,
according to the equation:2RSHþ 2½CuðNCÞ22þ ! ½CuðNCÞ2þ þRS-SRþ 2Hþ
The reduction of Cu(II) to Cu(I) in the presence of neocupr-
oine and subsequent complex formation between Cu(I) and
neocuproine takes few minutes to complete. Fig. 2 shows the
changes of the absorbance at 448 nm with time during the ﬁrst
few minutes from initiation of the reaction. As it is obvious,
the absorbance reaches a maximum after about 2 min and
remains constant afterwards. Therefore, all the absorbance
measurements were performed after 150 s from initiation of
the reaction.
3.1. Absorption spectrum
The reagent blank does not absorb in the visible range of
spectrum, but when captopril reacts with [Cu(NC)2]
2+, an
orange-yellow colored [Cu(NC)2]
+, is formed which has an
absorbance maximum at 448 nm and was stable for at least
2 h. The absorption spectra of the products and reagent blank
are shown in Fig. 3.
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Figure 4 Effect of pH on the absorbance. Conditions: neo-
cuproine concentration 5.0 · 103 M; Cu(II) concentration 1.0 ·
102 M; captopril concentration 3.0 lg mL1; temperature 25 C.
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Figure 5 Effect of neocuproine concentration on the absor-
bance. Conditions: pH 5.0 (acetate buffer); Cu(II) concentration
of 1.0 · 102 M; captopril concentration 3.0 lg mL1; tempera-
ture 25 C.
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Figure 6 Effect of Cu(II) concentration on the absorbance.
Conditions: pH 5.0 (acetate buffer); neocuproine concentration
5.0 · 103 M; captopril concentration 3.0 lg mL1; temperature
25 C.
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Figure 3 Absorption spectra of: (a) Cu(II)–neocuproine reagent
blank; (b) Cu(II)–neocuproine in the presence of 3.0 lg mL1
captopril.
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The effects of variables such as pH, concentration of neocupr-
oine and Cu(II) were studied to establish the best reaction con-
ditions for the maximum sensitivity.
3.2.1. Effect of pH
The effect of pH on the reduction of Cu(II) by captopril and
formation of Cu(I)–neocuproine complex was studied over
the pH range of (3.0–7.0) of acetate buffer solutions. Fig. 4
illustrates the effect of changing pH on the absorbance of
the solution mixture. The absorbance increased with increasing
pH up to 4.0 and remains constant to pH 6.0. Therefore, pH
5.0 was selected for further studies. The inﬂuence of pH on
Cu(II) reduction by captopril is expected since captopril has
a thiol group and H+ is involved in the oxidation–reduction
process of this thiol group.
3.2.2. Effect of neocuproine concentration
The effect of neocuproine concentration was examined over
the range 5 · 104 to 2.5 · 103 M. The results are shown in
Fig. 5. As it can be seen, at high concentrations of neocupro-
ine, the absorbance due to Cu(I)–neocuproine complexdecreases. This might be due to the fact that high concentra-
tions of neocuproine would result in a positive interference
from Cu(II) which could have arisen from incomplete conver-
sion of Cu(I) into the Cu(I)–neocuproine complex via mixed
ligand complex formation, as suggested by T¨utem and Apak
(1991). A 5.0 · 103 M neocuproine concentration was thus
chosen as the optimum conditions.
3.2.3. Effect of Cu(II) concentration
The inﬂuence of Cu(II) concentration on the absorbance in the
concentration range of 1.0 · 101 to 1.0 · 104 M of Cu(II)
was shown in Fig. 6. The oxidising power of Cu(II) in a solu-
tion containing neocuproine is dependent on the ease of for-
mation of [Cu(NC)2]
+. An excess of Cu(II) can exhibit an
afﬁnity for neocuproine, thereby preventing the preferential
quantitative formation of [Cu(NC)2]
+. Thus, large excess of
Cu(II) competes with Cu(I) for complex formation with neo-
cuproine. A 1.0 · 102 M was selected as the optimum Cu(II)
concentration.3.3. Analytical performance
3.3.1. Method validation
The validity of the method was tested regarding linearity, spec-
iﬁcity, accuracy, repeatability and precision according to ICH
Copper(II)–neocuproine reagent for spectrophotometric determination 163Q2B recommendations (Guidance for Industry Bioanalytical
method Validation et al., 2001).
3.3.1.1. Linearity. The absorbance–concentration plot was rec-
tilinear over the range of 0.3–3.0 lg mL1 with a minimum
detection limit of 0.039 lg mL1. Linear regression analysis
of the data gave the following equation:
A ¼ 4 103 þ 0:1877C ðr ¼ 0:9998Þ:
Where, A is the absorbance in 1 cm cell and C is the concen-
tration of the drug in lg mL1 and r is the correlation
coefﬁcient.
The limit of quantiﬁcation (LOQ) was determined by estab-
lishing the lowest concentration that can be measured accord-
ing to ICH Q2B (Guidance for Industry Bioanalytical method
Validation et al., 2001). The results are shown in Table 2. TheTable 2 Analytical parameters and application of the pro-
posed method and ofﬁcial method for the determination of
captopril in pure form.
Parameters Proposed
method
Oﬃcial
method (2)
Wavelengths, kmax (nm) 448
Beer’s law limits (lg mL1) 0.3–3.0
Ringbom limits (lg mL1) 0.5–2.7
Molar absorptivity e, (L/mol1 m1) 4.223 · 104
Sandell’s sensitivity (ng cm2) 5.15
Regression equation (y)a
Intercept (a) 0.004
Slope (b) 0.1877
Correlation coeﬃcient (r) 0.9998
LOD (lg mL1) 0.039
LOQ (lg mL1) 0.129
No. of experiments 6 3
Mean found (%± SD) 100.04 ± 0.75 99.89 ± 0.78
RSD 0.75 0.78
RE 0.307 0.45
Variance 0.56 0.61
Calculated t-value (2.36)b 0.23
Calculated F-value (5.79)b 1.08
RE, relative error; RSD, relative standard deviation; LOD, limit of
detection; LOQ, limit of quantiﬁcation; e, molar absorptivity
coefﬁcient.
a A= a+ bÆC, where, A is the absorbance, a is the intercept, b is
the slope and C is the concentration of drug in lg mL1.
b The theoretical values of t and F at P= 0.05.
Table 3 Evaluation of the inter-day and intraday precision and acc
Taken (lg mL1) Inter-day
Recoverya (%) Precision (RSD%)a Accuracy
0.5 98.94 1.12 1.06
1.0 99.57 0.92 0.43
2.0 99.92 0.81 0.08
3.0 100.20 0.108 0.20
0.5 98.94 1.12 1.06
RSD%, percentage relative standard deviation.
Er%, percentage relative error.
a Mean of ﬁve determination.limits of detection (LOD) were determined by establishing the
minimum level at which the analyte can be reliably detected,
and the results are also abridged in Table 2. LOQ and LOD
were calculated according to the following equation (Guidance
for Industry Bioanalytical method Validation et al., 2001):
LOQ ¼ 10r=S
LOD ¼ 3:3r=S:
Where, r: the standard deviation of the intercept of regres-
sion line. S: Slope of the calibration curve.
The proposed methods were evaluated for the accuracy as
percent relative error (% RE) and the precision as percent rel-
ative standard deviation (% RSD) (Table 2). Statistical analy-
sis (Miller and Miller, 2005) of the results, obtained by the
ofﬁcial (United States Pharmacopoeia et al., 2004) and the pro-
posed methods using student’s t-test and variance ratio F-test,
show no signiﬁcant difference between the performance of the
two methods regarding the accuracy and precision, respec-
tively (Table 2).
3.3.1.2. Precision, accuracy and speciﬁcity. In order to deter-
mine the accuracy and precision of the proposed methods,
solutions containing four different concentrations of captopril
were prepared and analyzed in six replicates. The relative stan-
dard deviation as precision and percentage relative error
(Er%) as accuracy of the suggested method were calculated
at 95% conﬁdence level can be considered satisfactory. Preci-
sion was carried out by six determinations at four different
concentrations. The percentage relative error calculated using
the following equation:Er% ¼ ½ðfounded addedÞ=added  100
The inter-day and intra-day precision and accuracy results
are shown in (Table 3). The analytical results of accuracy
and precision show that the proposed method has good repeat-
ability and reproducibility.
3.3.1.3. Robustness of the method. The robustness of the meth-
od adopted is demonstrated by the constancy of the absor-
bance with the deliberated minor changes in the experimental
parameters such as pH, volume of NC, 2.0 ± 0.2 mL, and
change in the volume of Cu(II) (1.0 · 102 M), ±0.1 mL.
These minor changes that may take place during the experi-
mental operation did not affect the absorbance of the reaction
product.uracy for captopril obtained by the proposed method.
Intraday
(Er%) Recoverya (%) Precisiona (RSD%) Accuracy (Er%)
99.90 0.66 0.10
99.92 0.90 0.08
99.30 0.45 0.70
100.15 1.17 0.15
99.90 0.66 0.10
Table 4 Application of the standard addition technique for the determination of captopril in pharmaceutical preparations using the
proposed method.
Preparations Taken (lg mL1) Added (lg mL1) Recoverya (%)
Proposed method Reference
method Sastry et al. (1996)
Capoten tabletsb (25 mg captopril/tablet) 0.5 – 100.90
0.5 101.20
1.0 101.05
1.5 101.30
2.0 99.80
2.5 100.50
Mean ± SD 101.09 ± 0.37 101.99 ± 0.54
te 3.07
Fe 2.13
Farcopril plus tabletsc (50 mg captopril and
25 mg of hydrochlorothiazide/tablet)
0.5 – 99.55
0.5 99.95
1.0 100.05
1.5 99.25
2.0 98.85
2.5 100.20
Mean ± SD 99.64 ± 0.52 100.48 ± 0.85
te 1.62
Fe 2.67
Capozide tabletsd (25 mg captopril and
12.5 mg of hydrochlorothiazide/tablet)
0.5 – 99.60
0.5 100.45
1.0 100.15
1.5 100.30
2.0 99.85
2.5 98.70
Mean ± SD 101.01 ± 0.65 101.99 ± 0.54
te 2.59
Fe 1.45
a Mean of three different experiments.
b Capoten tablets containing 25 mg of captopril each (batch # F91772) product of Bristol Myers Squibb Co., Giza, Egypt.
c Farcopril tablets containing 50 mg of captopril and 25 mg of hydrochlorothiazide each (batch # 843); product of Pharco pharmaceuticals
Alexandria, Egypt.
d Capozide tablets containing 50 mg of captopril each (batch # D91058) product of Smith Kline Beechane, LLC, (GSK), Giza, Egypt.
e Calculated t and F-values; tabulated t- and F-values for ﬁve degrees of freedom; and 95% conﬁdence limits (p= 0.05) are 2.36 and 5.79 (69).
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The criterion of interference was an error of not more than
±3.0% in the absorbance. To test the efﬁciency and selectivity
of the proposed method to pharmaceutical formulations. A
systematic quantitative study was undertaken by measuring
the absorbance of solutions containing 3.0 lg mL1 of capto-
pril by varying the additives and excipient such as glucose, lac-
tose, fructose, calcium, hydrogen phosphate, magnesium
stearate and starch. The excipients present in all tablets are
not interfering for drug. Hydrochlorothiazide which is fre-
quently co formulated with captopril in capozide and farcopril
plus tablets did not interfere with the proposed method.
3.5. Analytical applications
The proposed method was applied to the determination of
captopril in commercial tablets. Common tablet excipients
did not interfere with the assay. Moreover, to check the valid-
ity of the proposed method, dosage forms were tested for pos-
sible interference with standard addition method. The
performance of the proposed methods was assessed by calcula-tion of the t-test (for accuracy) and a variance ratio F-value
(for precision) compared with the ofﬁcial method (United
States Pharmacopoeia et al., 2004). (for 95% conﬁdence level
with ﬁve degrees of freedom (Miller and Miller, 2005)).
The results showed that the t- and F-values were less than
the critical value, indicating that there was no signiﬁcant dif-
ference between the proposed and reference method (Sastry
et al., 1996) for captopril as shown in Table 4. Because the pro-
posed method was more reproducible with high recoveries
than the reference method, they can be recommended for the
routine analysis in the majority of drug quality control
laboratories.4. Conclusions
A Cu(II)–neocuproine proved to be a suitable reagent for the
determination of captopril in pure form and its pharmaceutical
preparations. The high molar absorpitivity (e) of the proposed
method is a decisive advantage since the interference from
associated excipients was not observed. The proposed method
is simple, time saving and reproducible. Thus, the proposed
method can be used as an alternative for rapid and routine
Copper(II)–neocuproine reagent for spectrophotometric determination 165determination of captopril in bulk samples and various phar-
maceutical formulations in quality control and industry.
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